Relacorilant (Recorlev): A Patient Guide
Relacorilant (brand name Recorlev) is an oral prescription medicine that blocks some of the effects of cortisol. It is used to treat endogenous Cushing syndrome, a condition in which the body produces too much cortisol. It can help reduce symptoms caused by excess cortisol, but it does not treat the underlying cause.
Relacorilant lowers the effects of excess cortisol in adults with endogenous Cushing syndrome. Take it exactly as prescribed and ask your doctor or pharmacist about side effects, adrenal problems, and interactions with your other medicines.
Key facts at a glance
- RxNorm
- 2739519
- Generic
- Relacorilant
- Class
- unclassified
- Brands
- Lifyorli
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy